Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower earnings, on an adjusted basis, and revenues for the fourth quarter of 2023.
Total revenue declined 6% year-over-year to $2.39 billion. For the full year of 2024, the company expects revenues to decline in the mid-single digit percentage and projects adjusted earnings per share in the range of $15.00 to 16.00.
Net income attributable to Biogen Inc. was $249.7 million or $1.71 per share in Q4, compared to $550.4 million or $3.79 per share in the prior-year period. Adjusted earnings declined 27% to $2.95 per share in the December quarter.
Jerash Holdings (US), Inc. (NASDAQ: JRSH) reported significantly improved financial results for the fiscal 2026…
Shares of Prospect Capital Corporation (PSEC) traded mixed to slightly positive in early trading on…
Waters Corporation (WAT) shares dropped 14.49% to $326.04 in early trading on Tuesday after the…
Universal Corp. (UVV) shares fell 10.72% to $51.62 in Tuesday trading after the global agriproducts…
Upwork Inc (UPWK) shares fell 4.76% to $17.89 in early trading on Tuesday after the…
Amkor (NASDAQ: AMKR) posted net sales of $1888 million. Amkor Q4 2025 earnings showed robust…